Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.23 -2.02 (-4.09%)

Streaming Delayed Price Updated: 12:12 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Examining the Future: Sanofi's Earnings Outlook ↗

October 23, 2025

Via Benzinga

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

October 23, 2025

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

From Medidata Solutions, Inc.

Via GlobeNewswire

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy ↗

October 22, 2025

Sanofi revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101).

Via Benzinga

Why Immuneering Stock Soared Over 40% After-Hours Today ↗

September 24, 2025

Via Stocktwits

Is Sanofi Gaining or Losing Market Support? ↗

September 24, 2025

Via Benzinga

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease ↗

October 17, 2025

CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for new treatments.

Via Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗

October 09, 2025

The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.

Via Investor's Business Daily

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study ↗

October 08, 2025

Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroendocrine tumors.

Via Benzinga

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗

October 05, 2025

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.

Via The Motley Fool

AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine

October 02, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in...

Via TokenRing AI

Topics Artificial Intelligence Economy

Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism

October 01, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Novavax Amends Deal With Sanofi, Broadens Partnership ↗

September 30, 2025

The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.

Via Stocktwits

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Via Investor's Business Daily

Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data

September 27, 2025

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This...

Via MarketMinute

Amgen Expands US Manufacturing Network Amid New Tariff Policy ↗

September 26, 2025

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Via Benzinga

Topics Government World Trade

Sanofi Expands Insulin Savings Program To Cover All US Patients ↗

September 26, 2025

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ:...

Via Benzinga

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Via The Motley Fool

Topics Artificial Intelligence

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗

September 22, 2025

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Via Benzinga

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

September 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability ↗

September 17, 2025

Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions.

Via Benzinga

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗

September 15, 2025

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Via Benzinga

Topics Government

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday ↗

September 08, 2025

Via Benzinga

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 08, 2025

Via Benzinga

Why Nektar Therapeutics Rippled Higher This Week ↗

September 05, 2025

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.